Gold Ten Data, November 1st, China Jin published a report pointing out that the bank participated in the 2024 global brand strategy upgrade results conference organized by Meicaiyoupin (09896.HK), and conducted research on the newly opened Shanghai MINISOLAND store in October. The store's customer flow is like crucian carp, and Harry Potter IP sales are hot. The bank pointed out that the company is firmly developing two major directions: IP collaboration and brand globalization. It maintains its earnings forecast of RMB 2.15 and 2.59 per share for the next two years and maintains its outperform industry rating. Considering the fourth quarter entering the peak season to catalyze valuation improvement, the H-share target price is raised by 9% to HKD 44.6, corresponding to the forecast non-IFRS P/E ratio of 18 and 15 for the next two years.
Voir l'original
Cette page peut inclure du contenu de tiers fourni à des fins d'information uniquement. Gate ne garantit ni l'exactitude ni la validité de ces contenus, n’endosse pas les opinions exprimées, et ne fournit aucun conseil financier ou professionnel à travers ces informations. Voir la section Avertissement pour plus de détails.
CICC raised the target price of Innovent Biologics to HKD 44.6, firmly developing two major directions of IP co-branding and brand overseas expansion.
Gold Ten Data, November 1st, China Jin published a report pointing out that the bank participated in the 2024 global brand strategy upgrade results conference organized by Meicaiyoupin (09896.HK), and conducted research on the newly opened Shanghai MINISOLAND store in October. The store's customer flow is like crucian carp, and Harry Potter IP sales are hot. The bank pointed out that the company is firmly developing two major directions: IP collaboration and brand globalization. It maintains its earnings forecast of RMB 2.15 and 2.59 per share for the next two years and maintains its outperform industry rating. Considering the fourth quarter entering the peak season to catalyze valuation improvement, the H-share target price is raised by 9% to HKD 44.6, corresponding to the forecast non-IFRS P/E ratio of 18 and 15 for the next two years.